The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Key Considerations When Selecting Frontline Therapy in mCRC

Alan P. Venook, MD
Published Online:5:32 PM, Fri December 23, 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses key considerations in the selection of frontline therapy in metastatic colorectal cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.